The study not only reveals a new mechanism of breast cancer inhibition by melatonin through the regulation of BMAL1, a core gene of the biological clock, and its downstream metabolic pathways, but also highlights the important potential of melatonin or in combination with BMAL1 agonists in the future therapeutic strategy of breast cancer. This evidence concerns the gene CLOCK and breast cancer.